Clinical trials: Tamoxifen
Breast Neoplasms
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
This study is designed to evaluate the efficacy, safety, and pharmacokinetics of several immunotherapy-based combination treatments in participants with inoperable locally advanced or metastatic HR-positive, HER2-negative breast…
- Trial name
- MORPHEUS HR+BC (NCT03280563)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat
- Where
- 22 sites in United States, Israel and 1 more
- Volunteers
- 144 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
This trial studies the effects on quality of life and on time to second progression of the sequence endocrine therapy-capecitabine versus the sequence capecitabine-endocrine treatment.
- Trial name
- NCT00684216
- Testing
- capecitabine, hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- The Netherlands Cancer Institute
Early-stage Breast Cancer
Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Primarily, this clinical investigation compared the efficacy of cyclophosphamide + methotrexate + fluorouracil chemotherapy vs. goserelin + tamoxifen treatment in terms of prognosis (disease-free survival, overall survival) in…
- Trial name
- NCT00309478
- Testing
- Cyclophosphamide, Methotrexate, Fluorouracil implant
- Volunteers
- 1,099 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Neoplasms
Reversing Therapy Resistance With Epigenetic-Immune Modification
The investigators propose a randomized two arm trial, using Simon's 2-stage design, in ER+ patients with therapy resistant breast cancer to test the optimal sequence and dosing of epigenetic immune priming in hormone therapy…
- Trial name
- NCT02395627
- Testing
- Tamoxifen, Vorinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of California, San Francisco
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
This phase II trial tests the accuracy of functional imaging (FFNP)-positron emission tomography (PET)/computed tomography (CT) to predict response to abemaciclib plus endocrine therapy.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma
- Trial name
- NCT06179303
- Testing
- Abemaciclib, Anastrozole, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Depressive Syndrome
Osteoporosis Treatment in Post-menopausal Women
The study will be conducted to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.
- Trial name
- NCT03006003
- Testing
- Raloxifene, Alendronate
- Where
- 2 sites in Taiwan
- Volunteers
- 500 people
- Sponsor
- Taichung Veterans General Hospital
Breast Cancer
Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer
This is a clinical trial with a molecularly stratified parallel cohort, single arm design to explore the efficacy and safety of BKM120 in combination with tamoxifen in patients with ER/PR-positive, HER2-negative breast cancer…
- Trial name
- PIKTAM (NCT02404844)
- Testing
- BKM120, Tamoxifen
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- University Hospital, Essen
Breast Cancer
Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer
This is a biomedical and prospective study of interventional type. The trial will include 29 patients over a period of 15 months + 24 months of follow up maximum.
- Trial name
- MIRHO (NCT01612871)
- Testing
- Tamoxifen, Letrozole , Anastrozole, Exemestane
- Where
- 2 sites in France
- Volunteers
- 39 people
- Sponsor
- Institut Claudius Regaud
Endometrial Cancer
Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Trial name
- NCT00016341
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- 50 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Breast Cancer
Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Tamoxifen may fight breast cancer by blocking the use of estrogen.
- Trial name
- NCT00052728
- Testing
- tamoxifen citrate, tipifarnib
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
BRCA Mutation, PALB2 Gene Mutation
Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion
Circulating levels of Sex Hormone Binding Globulin (SHBG) are significantly associated with a decreased risk of breast cancer. The main aim of this clinical trial is to verify whether Low Dose Tamoxifen (LDT) increases…
- Conditions
- BRCA Mutation, PALB2 Gene Mutation, Ductal Carcinoma in Situ, Lobular Carcinoma in Situ
- Trial name
- TOLERANT (NCT06033092)
- Testing
- Tamoxifen 10 mg Tablet, Intermittent caloric restriction, Step counter Device
- Where
- 4 sites in Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
Bipolar Disorder
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas
1. Identify randomized controlled trials of tamoxifen (Estrogen Receptor modulator) in in addition to traditional treatment of bipolar disorder and synthesize the results using meta-analysis. 2.
- Trial name
- NCT06580535
- Testing
- blood sample
- Volunteers
- 100 people
- Sponsor
- Assiut University
Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).
- Conditions
- Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
- Trial name
- NCT04570956
- Testing
- Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- Mayo Clinic
Breast Cancer
Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer
We hypothesized that subjects with CYP2D6*10 alleles may have a lower steady state levels of endoxifen due to reduced conversion of tamoxifen to endoxifen.
- Trial name
- NCT00717015
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Early Breast Cancer
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of endocrine therapy in participants with medium- and high-risk…
- Trial name
- NCT04961996
- Testing
- Giredestrant, Physician's Choice of Endocrine Therapy, LHRH Agonist
- Where
- 621 sites in United States, Argentina and 52 more
- Volunteers
- 4,170 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease
Raloxifene for Women With Alzheimer's Disease
This is a multisite pilot randomized trial of raloxifene or placebo for the treatment of women with Alzheimer's disease.
- Trial name
- NCT00368459
- Testing
- raloxifene
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Stanford University
Breast Cancer, Menopausal Symptoms
Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer
RATIONALE: Raloxifene and exercise may improve bone health and quality of life in breast cancer survivors. Assessing bone health and quality of life may improve the ability to plan treatment.
- Conditions
- Breast Cancer, Menopausal Symptoms, Osteoporosis
- Trial name
- NCT00031811
- Testing
- raloxifene, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- OHSU Knight Cancer Institute
Amyotrophic Lateral Sclerosis
Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
The purpose of the study is to evaluate the safety and efficacy of high dose creatine and two dosages of tamoxifen treatment in amyotrophic lateral sclerosis (ALS).
- Trial name
- SDALS-001 (NCT01257581)
- Testing
- creatine, tamoxifen
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Nazem Atassi
Breast Neoplasms, Survival Analysis
Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients
The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen. The investigators want to evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6…
- Conditions
- Breast Neoplasms, Survival Analysis, Antineoplastic Agents, Therapeutic Uses
- Trial name
- NCT01169792
- Testing
- tamoxifen
- Where
- 2 sites in South Korea
- Sponsor
- Yonsei University
Breast Cancer
Adjuvant Post-Tamoxifen Exemestane Trial
The ATENA phase III randomized parallel-group multicenter trial is designed to compare 5 years of adjuvant exemestane versus 5 years of observation in postmenopausal women with operable breast cancer who have received 5-7 years…
- Trial name
- ATENA (NCT00810706)
- Testing
- exemestane
- Where
- Greece
- Volunteers
- 448 people
- Sponsor
- Hellenic Breast Surgeons Society